BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients

Phase 2

Terminated

Conditions: Cystic Fibrosis

Interventions: Drug: Riociguat (Adempas, BAY63-2521)
Drug: Placebo

First Posted Date: 2014-06-23

Last Posted Date: 2023-11-07

Lead Sponsor: Bayer

Target Recruit Count: 21

Registration Number: NCT02170025

Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer

Phase 1

Terminated

Conditions: Neoplasms

Interventions: Drug: Refametinib (BAY86-9766)
Drug: Regorafenib (Stivarga, BAY73-4506)

First Posted Date: 2014-06-20

Last Posted Date: 2018-01-26

Lead Sponsor: Bayer

Target Recruit Count: 20

Registration Number: NCT02168777

RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Small Cell Lung Carcinoma

Interventions: Drug: Roniciclib (BAY1000394)
Drug: Placebo

First Posted Date: 2014-06-11

Last Posted Date: 2018-06-25

Lead Sponsor: Bayer

Target Recruit Count: 142

Registration Number: NCT02161419

Relative Bioavailability Study

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Riociguat(Adempas,BAY63-2521)

First Posted Date: 2014-06-09

Last Posted Date: 2016-02-18

Lead Sponsor: Bayer

Target Recruit Count: 48

Registration Number: NCT02159313

Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women

Phase 1

Completed

Conditions: Drug Interactions

Interventions: Drug: Microgynon
Drug: Riociguat (Adempas,BAY63-2521)

First Posted Date: 2014-06-09

Last Posted Date: 2015-08-14

Lead Sponsor: Bayer

Target Recruit Count: 31

Registration Number: NCT02159326

Assess Satisfaction of Patients and Physicians With Results of Yaz Plus Treatment for 13 Cycles

Completed

Conditions: Contraception

Interventions: Drug: BAY98-7071_EE20/DRSP/L-5-MTHF

First Posted Date: 2014-06-09

Last Posted Date: 2017-08-09

Lead Sponsor: Bayer

Target Recruit Count: 1500

Registration Number: NCT02159261

Copanlisib Pharmacodynamic Study

Phase 1

Completed

Conditions: Non Hodgkin Lymphoma

Interventions: Drug: Copanlisib (BAY80-6946)

First Posted Date: 2014-06-04

Last Posted Date: 2017-06-16

Lead Sponsor: Bayer

Target Recruit Count: 63

Registration Number: NCT02155582

Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer

Completed

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223)

First Posted Date: 2014-05-19

Last Posted Date: 2024-11-22

Lead Sponsor: Bayer

Target Recruit Count: 1474

Registration Number: NCT02141438

Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel

Phase 1

Terminated

Conditions: Medical Oncology

Interventions: Drug: BAY1161909
Drug: Paclitaxel

First Posted Date: 2014-05-15

Last Posted Date: 2018-10-12

Lead Sponsor: Bayer

Target Recruit Count: 69

Registration Number: NCT02138812

Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)

Phase 2

Terminated

Conditions: Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary

Interventions: Drug: Riociguat (Adempas, BAY63-2521)
Drug: Placebo

First Posted Date: 2014-05-15

Last Posted Date: 2017-12-04

Lead Sponsor: Bayer

Target Recruit Count: 147

Registration Number: NCT02138825

Locations: 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
Via Christi Clinic, Wichita, Kansas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy